Department of Molecular Sciences, "Iuliu Hatieganu" University of Medicine and Pharmacy, Pasteur Street, No 6, 400349, Cluj-Napoca, Romania.
Emergency Clinical Hospital for Children, Pasteur Street, No 6, 400349, Cluj-Napoca, Romania.
Ital J Pediatr. 2022 Dec 30;48(1):207. doi: 10.1186/s13052-022-01397-1.
Developmental delay and intellectual disability represent a common pathology in general population, involving about 3% of the pediatric age population, the genetic etiology being often involved. The aim of this study was to determine the clinically relevant copy number variants in patients diagnosed with global developmental delay/intellectual disability in our population, using the chromosomal microarray analysis.
We analyzed 189 patients diagnosed with global developmental delay/intellectual disability, presented in Clinical Emergency Hospital for Children, Cluj-Napoca. The patients were completely clinically investigated, including dysmorphic and internal malformations evaluation, psychiatric, neuropsychological and metabolic evaluation, standard karyotyping. Genomic analysis was done using chromosomal microarray analysis.
Pathogenic findings (including uniparental disomy) and variants of unknown significance were detected in 53 of 189 patients (28.04%). Pathogenic copy number variants and uniparental disomy were observed in 35 of 189 patients (18.51%). Two patients presented uniparental disomy for chromosome 15, one with clinical phenotype of Prader-Willi syndrome and the other with clinical phenotype with Angelman syndrome. Within the category of pathogenic findings, the recurrent copy number variants were seen in 21 of 35 patients (60%).
The increased percentage of pathogenic structural variants observed in patients with global developmental delay/intellectual disability analyzed by chromosomal microarray technique supports its use in patients with a non-specific phenotype such as these neurodevelopmental disorders. The high percentage of recurrent pathogenic variants between these findings is a finding that support their initial evaluation when a genetic testing algorithm could be a useful option.
发育迟缓与智力障碍是一种常见的病理学表现,在儿科人群中约占 3%,其遗传病因常涉及其中。本研究旨在通过染色体微阵列分析,确定在我们人群中被诊断为全面发育迟缓/智力障碍的患者中具有临床意义的拷贝数变异。
我们分析了 189 名在克卢日-纳波卡儿童临床急诊医院就诊的被诊断为全面发育迟缓/智力障碍的患者。对患者进行了全面的临床评估,包括对畸形和内部畸形的评估、精神科、神经心理学和代谢评估、标准核型分析。使用染色体微阵列分析进行基因组分析。
在 189 名患者中的 53 名(28.04%)中发现了致病性发现(包括单亲二倍体)和意义不明的变体。在 189 名患者中的 35 名(18.51%)中观察到致病性拷贝数变异和单亲二倍体。两名患者存在 15 号染色体单亲二倍体,其中一名患者具有 Prader-Willi 综合征的临床表型,另一名患者具有 Angelman 综合征的临床表型。在致病性发现类别中,在 21 名患者(60%)中观察到反复出现的拷贝数变异。
通过染色体微阵列技术分析,在患有全面发育迟缓/智力障碍的患者中观察到致病性结构变异的百分比增加,这支持了该技术在这些神经发育障碍等非特异性表型患者中的应用。在这些发现中反复出现的高比例致病性变异是支持对其进行初始评估的发现,当遗传测试算法可能是一种有用的选择时。